Literature DB >> 25904750

Immune Mechanisms Are Major Players in Cancer.

Karl Erik Hellstrom1, Ingegerd Hellstrom2.   

Abstract

Vaccination with sipuleucel-T produced IgG antibodies to secondary prostatic carcinoma antigens and prolonged survival in some patients, and assaying for antibodies may provide prognostic information and identify new vaccine targets. Additional approaches to improve T-cell responses are needed to improve the clinical efficacy. See related article by GuhaThakurta et al., p. 3619. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25904750      PMCID： PMC4537829          DOI： 10.1158/1078-0432.CCR-15-0531

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.

Authors:  Debraj GuhaThakurta; Nadeem A Sheikh; Li-Qun Fan; Harini Kandadi; T Craig Meagher; Simon J Hall; Philip W Kantoff; Celestia S Higano; Eric J Small; Thomas A Gardner; Kate Bailey; Tuyen Vu; Todd DeVries; James B Whitmore; Mark W Frohlich; James B Trager; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

3.  Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.

Authors:  Min Dai; Yuen Yee Yip; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Clin Cancer Res       Date:  2014-08-20       Impact factor: 12.531

4.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

Authors:  I Melero; W W Shuford; S A Newby; A Aruffo; J A Ledbetter; K E Hellström; R S Mittler; L Chen
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

Review 5.  Cellular immunity against tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Cancer Res       Date:  1969       Impact factor: 6.242

Review 6.  The role of the CD28 receptor during T cell responses to antigen.

Authors:  P S Linsley; J A Ledbetter
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

7.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

Authors:  L Chen; S Ashe; W A Brady; I Hellström; K E Hellström; J A Ledbetter; P McGowan; P S Linsley
Journal:  Cell       Date:  1992-12-24       Impact factor: 41.582

8.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

Review 9.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

10.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245
View more
  1 in total

1.  CD137-CRDI is not necessary in the role of contacting its natural ligand.

Authors:  Ling Yi; Zhuohong Yan; Hongyan Jia; Xiaojue Wang; Yanlin Zhao; Hongtao Zhang
Journal:  Immunol Cell Biol       Date:  2016-08-16       Impact factor: 5.126
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.